

Chemicals/Finland, May 3, 2023 Company update

Preparing for larger volumes

Exel's Q1 was expected to be soft but it turned out quite weak. This year will continue to see rather modest profitability while long-term potential still exists.

Weakness largely attributable to low Wind power volumes Exel's Q1 revenue fell 16% y/y to EUR 28.8m vs the EUR 32.2m/33.6m Evli/cons. estimates. H1 was seen soft due to lacking Wind power orders however such volumes came in at EUR 1.5m in Q1 vs our EUR 5.9m estimate. The figure was lower than Exel expected, in addition to which there was softness in Equipment and other industries. Transportation still saw strong development, yet small and mid-sized customers continued to reduce inventories as seen already in H2'22. Exel has already taken some cost actions and although there weren't any notable cost-related surprises the demand softness led to an adj. EBIT of EUR 0.0m, compared to the EUR 1.2m/1.4m Evli/cons. estimates. Exel consequently downgraded its guidance as any significant demand recovery is unlikely to begin before H2'23, while the company will also incur some EUR 1m in additional expenses this

We also cut our FY '24 EBIT estimate by more than 20%

year as it seeks to ensure its competitiveness within Wind power.

Wind power's development program is unlikely to change the company's focus on turbine blade reinforcement elements; rather it should enhance Exel's ability to deliver the needed volumes. Wind power may see some volume improvement already later this year, but the next couple of quarters are likely to remain soft before high growth again really begins to come through next year. Wind power aside, Exel looks to better capture sustained growth by focusing more on larger accounts. Exel's strategy worked well in the past few years as it achieved a CAGR of 12% in FY '19-21 however now seems to be a time for enhancing commercial focus. Such strategy themes (focus on high-volume accounts) aren't very surprising in the light of Exel's business model, in which a relatively high amount of customer account concentration tends to optimize profitability.

Valuation not particularly cheap in the short-term

Exel has a lot more potential thanks to its existing applications and their further scaling over the coming years, yet the 13x and 8x EV/EBIT multiples appear neutral on our estimates for FY '23-24. Our new TP is EUR 4.3 (5.8); our rating is now HOLD (BUY).



■ BUY □ HOLD ■ SELL

KEY FIGU	RES									
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR
2021	134.4	3.7	2.8%	-6.2	0.14	57.0	1.0	34.9	-6.5	0.20
2022	137.0	3.0	2.2%	9.4	0.18	30.1	0.7	31.4	14.6	0.20
2023E	129.9	5.8	4.5%	5.9	0.18	22.2	0.6	12.8	12.3	0.20
2024E	139.6	8.9	6.4%	5.4	0.44	9.1	0.5	8.0	11.3	0.25
2025E	146.6	11.9	8.1%	7.9	0.65	6.3	0.5	5.6	16.4	0.30
Market cap	, EURm		48 G	earing 2023E,	0/0		86.8 CAGR	EPS 2022-2	5, %	53.1
Net debt 2	023E, EURm		26 P	rice/book 2023	BE		1.6 CAGR	sales 2022-	25, %	2.3
Enterprise	value, EURm		74 D	ividend yield 2	2023E, %		4.9 ROE 2	023E, %		7.1
Total assets	s 2023E, EURn	n	107 Ta	ax rate 2023E,	0/0		44.7 ROCE	2023E, %		6.1
Goodwill 2	023E, EURm		13 E	quity ratio 202	23E, %		28.2 PEG, P	P/E 23/CAGR		0.3



Chemicals/Finland, May 3, 2023 Company update

Estimates and peer group multiples

Exel Composites	2019	2020	2021	Q1'22	Q2'22	Q3'22	Q4'22	2022	Q1'23	Q2'23e	Q3'23e	Q4'23e	2023e
Buildings and infrastructure	23.5	23.5	32.9	7.7	8.9	7.8	8.1	32.5	7.8	7.7	8.4	9.0	32.9
Equipment and other industrie	18.6	19.5	23.4	7.4	5.9	5.6	4.3	23.1	5.6	5.1	4.9	4.9	20.5
Wind power	23.6	28.1	32.1	6.8	6.5	8.0	5.5	26.8	1.5	4.0	5.2	5.9	16.5
Machinery and electrical	14.4	15.5	17.6	4.3	5.3	5.0	5.2	19.7	4.6	5.5	5.1	5.5	20.7
Transportation	13.1	10.2	10.2	3.1	7.2	3.7	3.3	17.4	4.2	8.0	4.9	4.5	21.7
Defense	2.3	5.3	8.7	2.1	1.6	2.0	1.9	7.5	2.9	1.6	2.1	2.0	8.7
Telecommunications	8.2	6.5	9.5	2.8	2.8	1.7	2.6	10.0	2.2	2.5	1.6	2.7	9.0
Revenue	103.8	108.6	134.4	34.2	38.1	33.8	31.0	137.0	28.8	34.3	32.2	34.6	129.9
y/y change, %	7 %	5 %	24 %	10 %	14 %	1 %	-15 %	2 %	-16 %	-10 %	-5 %	12 %	-5 %
Adjusted EBIT	7.2	9.7	6.0	2.2	3.1	1.8	0.9	8.0	0.0	1.2	2.2	2.7	6.1
EBIT	5.1	9.4	3.7	0.0	3.0	1.7	-1.7	3.0	-0.3				5.8
-margin, %	6.9 %	8.9 %	4.5 %	6.4 %	8.2 %	5.4 %	3.0 %	5.9 %	0.0 %	3.5 %	6.8 %	7.8 %	4.7 %
-margin (reported), %	4.9 %	8.7 %	2.8 %	0.1 %	7.9 %	5.0 %	-5.5 %	2.2 %	-1.0 %				4.5 %

Source: Evli Research

	MCAP		EV/EBITDA			EV/EBIT			EBIT-%	
EXEL COMPOSITES PEER GROUP	MEUR	22	23	24	22	23	24	22	23	24
Hexagon Composites	544		116.3x	36.0x				-8.0 %	-7.4 %	-3.0 %
Hexcel	5554	19.0x	18.1x	15.2x	31.6x	27.9x	22.0x	11.4 %	13.5 %	15.5 %
Avient	3183	8.0x	9.6x	8.6x	11.7x	15.1x	12.6x	11.9 %	9.7 %	11.0 %
SGL Carbon	1110	6.0x	8.1x	7.1x	9.9x	12.3x	10.4x	9.9 %	9.9 %	11.0 %
TPI Composites	437	13.1x	17.3x	8.2x			16.5x	-1.5 %	-0.6 %	2.7 %
Peer Group Average	2166	11.5x	33.9x	15.0x	17.7x	18.4x	15.4x	4.7 %	5.0 %	7.4 %
Peer Group Median	1110	10.6x	17.3x	8.6x	11.7x	15.1x	14.5x	9.9 %	9.7 %	11.0 %
Exel Composites (Evli est.)	49	9.3x	6.2x	4.8x	31.4x	12.9x	8.0x	2.2 %	4.5 %	6.4 %

Exel Composites prem./disc. to peer median

-12 %

-64 %

-44 %

168 % -15 % -45 %

-78 %

-54 % -42 %

Source FactSet, Evli Research

Chemicals/Finland, May 3, 2023 Company update

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC	
Current share price	4.05 PV of Free Cash Flow	76 Long-term growth, %	1.5 Risk-free interest rate, %	2.25
DCF share value	11.54 PV of Horizon value	95 WACC, %	8.5 Market risk premium, %	5.8
Share price potential, %	184.9 Unconsolidated equity	0 Spread, %	0.5 Debt risk premium, %	3.3
Maximum value	12.7 Marketable securities	17 Minimum WACC, %	8.0 Equity beta coefficient	1.00
Minimum value	10.5 Debt - dividend	-50 Maximum WACC, %	9.0 Target debt ratio, %	10
Horizon value, %	55.6 Value of stock	138 Nr of shares, Mn	11.9 Effective tax rate, %	21

T												1
DCF valuation, EURm	2022	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	Horizon
Net sales	137	130	140	147	151	154	157	160	163	167	169	172
Sales growth, %	2.0	-5.2	7.5	5.0	3.0	2.0	2.0	2.0	2.0	2.0	1.5	1.5
Operating income (EBIT)	3	6	9	12	14	16	17	18	19	19	19	20
Operating income margin, %	2.2	4.5	6.4	8.1	9.0	10.5	11.0	11.5	11.5	11.5	11.5	11.5
+ Depreciation+amort.	7	6	6	6	5	5	5	4	4	4	4	
EBITDA	10	12	15	17	19	21	22	23	23	24	24	
- Paid taxes	-1	-2	-2	-3	-3	-4	-4	- 5	-5	-5	-5	
- Change in NWC	3	1	-1	-1	-1	0	0	0	0	0	0	
NWC / Sales, %	10.3	10.1	10.4	10.6	10.8	10.8	10.9	11.0	11.1	11.1	11.2	
+ Change in other liabs	0	0	0	0	0	0	0	0	0	0	0	
- Operative CAPEX	-3	-3	-4	-4	-4	-4	-4	-4	-4	-4	-4	
opCAPEX / Sales, %	2.4	2.7	3.1	3.0	2.9	2.6	2.6	2.6	2.6	2.6	2.6	
- Acquisitions	0	0	0	0	0	0	0	0	0	0	0	
+ Divestments	0	0	0	0	0	0	0	0	0	0	0	
- Other items	0	0	0	0	0	0	0	0	0	0	0	
= FCFF	9	8	7	10	11	13	13	14	14	14	15	210
= Discounted FCFF		7	6	8	8	9	8	8	7	7	7	95
= DFCF min WACC	•	7	6	8	8	9	9	8	8	7	7	107
= DFCF max WACC	•	7	6	8	8	8	8	8	7	7	6	85

Chemicals/Finland, May 3, 2023 Company update

INTERIM FIGURES

EVLI ESTIMATES. EURm	2022Q1	202202	2022Q3	2022Q4	2022	2023Q1	2023Q2E	2023Q3E	2023Q4E	2023E	2024E	2025E
Net sales	34.2	38.1	33.8	31.0	137.0	28.8	34.3	32.2	34.6	129.9	139.6	146.6
EBITDA	1.8	4.8	3.6	0.0	10.1	1.5	2.7	3.7	4.2	12.0	14.9	17.4
EBITDA margin (%)	5.2	12.5	10.5	0.0	7.4	5.3	7.8	11.4	12.1	9.3	10.6	11.9
EBIT	0.0	3.0	1.7	-1.7	3.0	-0.3	1.2	2.2	2.7	5.8	8.9	11.9
EBIT margin (%)	0.1	7.9	5.0	-5.5	2.2	-1.0	3.5	6.8	7.8	4.5	6.4	8.1
Net financial items	0.5	1.9	1.6	-3.4	0.6	-1.2	-0.3	-0.2	-0.2	-1.9	-1.7	-1.6
Pre-tax profit	0.5	4.9	3.3	-5.1	3.6	-1.5	0.9	2.0	2.5	3.9	7.3	10.3
Tax	-0.6	-0.9	-1.2	1.2	-1.5	-0.6	-0.3	-0.3	-0.5	-1.7	-2.0	-2.6
Tax rate (%)	111.4	19.3	35.6	24.3	40.4	-43.8	33.3	15.0	20.0	44.7	27.4	25.0
Net profit	-0.1	4.0	2.1	-3.9	2.1	-2.1	0.6	1.7	2.0	2.2	5.3	7.7
EPS	-0.01	0.33	0.18	-0.33	0.18	-0.18	0.05	0.14	0.17	0.18	0.44	0.65
EPS adjusted (diluted no. of shares)	-0.01	0.33	0.18	-0.33	0.18	-0.18	0.05	0.14	0.17	0.18	0.44	0.65
Dividend per share	0.00	0.00	0.00	0.00	0.20	0.00	0.00	0.00	0.00	0.20	0.25	0.30
SALES, EURm												
Exel Composites	34.2	38.1	33.8	31.0	137.0	28.8	34.3	32.2	34.6	129.9	139.6	146.6
Total	34.2	38.1	33.8	31.0	137.0	28.8	34.3	32.2	34.6	129.9	139.6	146.6
SALES GROWTH, Y/Y %												
Exel Composites	10.3	13.5	1.2	-15.1	2.0	-15.7	-9.9	-4.7	11.6	-5.2	7.5	5.0
Total	10.3	13.5	1.2	-15.1	2.0	-15.7	-9.9	-4.7	11.6	-5.2	7.5	5.0
EBIT, EURm												
Exel Composites	0.0	3.0	1.7	-1.7	3.0	-0.3	1.2	2.2	2.7	5.8	8.9	11.9
Total	0.0	3.0	1.7	-1.7	3.0	-0.3	1.2	2.2	2.7	5.8	8.9	11.9
EBIT margin, %										·	•	
Exel Composites	0.1	7.9	5.0	-5.5	2.2	-1.0	3.5	6.8	7.8	4.5	6.4	8.1
Total	0.1	7.9	5.0	-5.5	2.2	-1.0	3.5	6.8	7.8	4.5	6.4	8.1

Chemicals/Finland, May 3, 2023 Company update

								2025E
Sales	96.6	103.8	108.6	134.4	137.0	129.9	139.6	146.6
Sales growth (%)	11.9	7.5	4.6	23.7	2.0	-5.2	7.5	5.0
EBITDA	7.7	10.7	15.3	11.9	10.1	12.0	14.9	17.4
EBITDA margin (%)	8.0	10.3	14.1	8.9	7.4	9.3	10.6	11.9
Depreciation	-5.5	-5.6	-5.8	-8.2	-7.1	-6.2	-5.9	-5.6
EBITA	2.2	5.1	9.4	3.7	3.0	5.8	8.9	11.9
Goodwill amortization / writedown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	2.2	5.1	9.4	3.7	3.0	5.8	8.9	11.9
EBIT margin (%)	2.3	4.9	8.7	2.8	2.2	4.5	6.4	8.1
Reported EBIT	2.2	5.1	9.4	3.7	3.0	5.8	8.9	11.9
EBIT margin (reported) (%)	2.3	4.9	8.7	2.8	2.2	4.5	6.4	8.1
Net financials	-0.5	-1.2	-2.3	0.4	0.6	-1.9	-1.7	-1.6
Pre-tax profit	1.7	3.9	7.1	4.2	3.6	3.9	7.3	10.3
Taxes	-1.3	-1.5	-1.7	-2.5	-1.5	-1.7	-2.0	-2.6
Minority shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit	0.4	2.4	5.4	1.7	2.1	2.2	5.3	7.7
Cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET, EURm								
Assets								
Fixed assets	21	23	30	34	31	28	26	25
Goodwill	13	13	13	13	13	13	13	13
Right of use assets	5	5	3	3	2	2	2	2
Inventory	15	17	16	24	23	22	24	25
Receivables	20	20	21	26	24	23	25	26
Liquid funds	5	7	12	16	17	16	18	19
Total assets	79	85	97	118	113	107	110	112
Liabilities								
Shareholder's equity	26	26	29	31	30	30	33	38
Minority interest	0	0	0	0	0	0	0	0
Convertibles	0	0	0	0	0	0	0	0
Lease liabilities	3	4	2	2	1	2	2	2
Deferred taxes	0	0	0	0	1	1	1	1
Interest bearing debt	30	32	40	50	46	41	39	35
Non-interest bearing current liabilities	18	21	24	32	26	25	27	28
Other interest-free debt	2	2	2	3	9	9	9	9
Total liabilities	79	85	97	118	113	107	110	112
CASH FLOW, EURm								
+ EBITDA	8	11	15	12	10	12	15	17
- Net financial items	0	-1	-2	0	1	-2	-2	-2
- Taxes	-2	-2	-2	-3	-1	-2	-2	-3
- Increase in Net Working Capital	-4	1	3	-5	3	1	-1	-1
+/- Other	0	0	0	0	0	0	0	0
= Cash flow from operations	1	8	13	5	13	9	10	12
- Capex	-10	-8	-13	-11	-3	-4	-4	-4
- Acquisitions	0	Ō	0	0	0	0	0	0
+ Divestments	0	0	0	0	0	0	0	0
= Free cash flow	-9	1	0	-6	9	6	5	8
+/- New issues/buybacks	0	0	-1	3	-1	0	0	0
- Paid dividend	-4	-2	-2	-2	-2	-2	-2	-3
+/- Other	9	3	7	9	-5	-4	-2	-4
Change in cash	-3	2	5	4	2	-1	1	1

Chemicals/Finland, May 3, 2023 Company update

KEY FIGURES	2019	2020	2021	2022	2023E	2024E	2025E
M-cap	78	88	94	64	48	48	48
Net debt (excl. convertibles)	29	30	36	30	26	23	18
Enterprise value	107	118	131	94	74	71	66
Sales	104	109	134	137	130	140	147
EBITDA	11	15	12	10	12	15	17
EBIT	5	9	4	3	6	9	12
Pre-tax	4	7	4	4	4	7	10
Earnings	2	5	2	2	2	5	8
Equity book value (excl. minorities)	26	29	31	30	30	33	38
Valuation multiples		-	-				
EV/sales	1.0	1.1	1.0	0.7	0.6	0.5	0.5
EV/EBITDA	10.0	7.7	10.9	9.3	6.2	4.8	3.8
EV/EBITA	21.0	12.5	34.9	31.4	12.8	8.0	5.6
EV/EBIT	21.0	12.5	34.9	31.4	12.8	8.0	5.6
EV/OCF	12.9	8.8	27.2	7.4	7.9	7.3	5.4
EV/FCFF	32.5	52.9	-26.0	10.2	9.7	9.8	6.8
P/FCFE	110.9	179.1	-15.3	6.8	8.1	8.9	6.1
P/E	32.5		-15.3 57.0		22.2		6.3
r/c P/B		16.4		30.1		9.1	
•	3.0	3.1	3.0	2.1	1.6	1.5	1.3
Target EV/EBITDA	0.0	0.0	0.0	0.0	6.4	5.0	4.0
Target EV/EBIT	0.0	0.0	0.0	0.0	13.3	8.3	5.8
Target EV/FCF	0.0	0.0	0.0	0.0	13.0	13.7	8.8
Target P/B	0.0	0.0	0.0	0.0	1.7	1.5	1.4
Target P/E	0.0	0.0	0.0	0.0	23.6	9.7	6.6
Per share measures							
Number of shares	11,897	11,897	11,897	11,897	11,897	11,897	11,897
Number of shares (diluted)	11,897	11,897	11,897	11,897	11,897	11,897	11,897
EPS	0.20	0.45	0.14	0.18	0.18	0.44	0.65
Operating cash flow per share	0.70	1.12	0.40	1.06	0.79	0.82	1.03
Free cash flow per share	0.06	0.04	-0.52	0.79	0.50	0.46	0.66
Book value per share	2.21	2.41	2.62	2.56	2.54	2.78	3.18
Dividend per share	0.18	0.20	0.20	0.20	0.20	0.25	0.30
Dividend payout ratio, %	89.2	44.3	143.7	110.9	109.8	56.3	46.3
Dividend yield, %	2.7	2.7	2.5	3.7	4.9	6.2	7.4
FCF yield, %	0.9	0.6	-6.5	14.6	12.3	11.3	16.4
Efficiency measures							
ROE							017
	9.2	19.5	5.5	7.0	7.1	16.7	21.7
ROCE	9.2 8.6	19.5 14.4	5.5 5.1	7.0 4.0	7.1 6.1	16.7 10.8	14.6
ROCE Financial ratios							
Financial ratios	8.6	14.4	5.1	4.0	6.1	10.8	14.6
Financial ratios Inventories as % of sales	16.3	14.4	5.1 17.8	4.0 17.1	6.1 17.1	10.8	14.6
Financial ratios Inventories as % of sales Receivables as % of sales	8.6 16.3 19.2	14.4 14.9 19.2	5.1 17.8 19.6	17.1 17.8	6.1 17.1 17.8	10.8 17.1 17.8	14.6 17.1 17.7
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales	8.6 16.3 19.2 20.2	14.4 14.9 19.2 22.0	5.1 17.8 19.6 23.8	4.0 17.1 17.8 19.1	17.1 17.8 19.1	17.1 17.8 19.1	14.6 17.1 17.7 19.1
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, %	8.6 16.3 19.2 20.2 14.1	14.4 14.9 19.2 22.0 11.2	5.1 17.8 19.6 23.8 12.7	17.1 17.8 19.1 10.3	17.1 17.8 19.1 10.1	17.1 17.8 19.1 10.4	14.6 17.1 17.7 19.1 10.6
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), %	8.6 16.3 19.2 20.2 14.1 7.3 7.3	14.4 14.9 19.2 22.0 11.2 11.9	5.1 17.8 19.6 23.8 12.7 8.2 8.2	17.1 17.8 19.1 10.3 2.4	17.1 17.8 19.1 10.1 2.7 2.7	17.1 17.8 19.1 10.4 3.1 3.1	14.6 17.1 17.7 19.1 10.6 3.0 3.0
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3	14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1	5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4	17.1 17.8 19.1 10.3 2.4 2.4 0.9	17.1 17.8 19.1 10.1 2.7 2.7 0.6	10.8 17.1 17.8 19.1 10.4 3.1 3.1 0.5	17.1 17.7 19.1 10.6 3.0 3.0 0.6
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3 2.7	14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1 2.0	5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4 3.0	17.1 17.8 19.1 10.3 2.4 2.4 0.9 2.9	17.1 17.8 19.1 10.1 2.7 2.7 0.6 2.2	10.8 17.1 17.8 19.1 10.4 3.1 3.1 0.5 1.6	17.1 17.7 19.1 10.6 3.0 3.0 0.6 1.0
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3	14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1	5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4	17.1 17.8 19.1 10.3 2.4 2.4 0.9	17.1 17.8 19.1 10.1 2.7 2.7 0.6	10.8 17.1 17.8 19.1 10.4 3.1 3.1 0.5	17.1 17.7 19.1 10.6 3.0 3.0 0.6

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, May 3, 2023 Company update

COMPANY DESCRIPTION: Exel Composites manufactures composites profiles for various demanding, mainly industrial end-use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

INVESTMENT CASE: Our positive view is based on good long-term composites demand outlook, coupled with the fact that Exel Composites' current manufacturing footprint could support annual revenue in the EUR 150m ballpark i.e. there's still plenty of room to improve delivery volumes. Exel's rather high fixed cost base translates to meaningful operating leverage, and thus higher revenues should lead to improving operating margins. The company is also progressing well with its cost savings program. Operating profit could further significantly improve if good execution continues. Recently the wind energy sector has provided great lift for volumes; other attractive applications include e.g. transportation industry profiles.

OWNERSHIP STRUCTURE	SHARES	EURm	0/0
Sijoitusrahasto Taaleritehdas Mikro Markka	800,000	3.240	6.7%
OP-Finland Small Firms Fund	590,119	2.390	5.0%
Ilmarinen Mutual Pension Insurance	496,547	2.011	4.2%
Op-Suomi Mikroyhtiöt -Erikoissijoitusrahasto	420,000	1.701	3.5%
Phoebus Fund	370,000	1.499	3.1%
Säästöpankki Pienyhtiöt	288,710	1.169	2.4%
Nelimarkka Heikki Antero	213,545	0.865	1.8%
Veritas Pension Insurance Company Ltd.	207,479	0.840	1.7%
Säästöpankki Kotimaa	132,680	0.537	1.1%
Sumato Oy	131,821	0.534	1.1%
Ten largest	3,650,901	14.786	31%
Residual	8,245,942	33.396	69%
Total	11,896,843	48.182	100%

EARNINGS CALENDAR	
August 18, 2023	Q2 report
November 03, 2023	Q3 report
OTHER EVENTS	

COMPANY MISCELLANEOUS

CEO: Paul Sohlberg CFO: Mikko Rummukainen IR: Sanna Ahvenniemi Mäkituvantie 5 01510 Vantaa Tel: +358 20 7541 200

Chemicals/Finland, May 3, 2023 Company update

DEFINITIONS

P/E	EPS
	LIJ
Price per share Earnings per share	Profit before extraord. items and taxes- income taxes + minority interest Number of shares
P/BV	DPS
Price per share Shareholders' equity + taxed provisions per share	Dividend for the financial period per share
Market cap	OCF (Operating cash flow)
Price per share * Number of shares	EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments
EV (Enterprise value)	FCF (Free cash flow)
Market cap + net debt + minority interest at market value – share of associated companies at market value	Operating cash flow – operative CAPEX – acquisitions + divestments
EV/Sales	FCF yield, %
Enterprise value Sales	Free cash flow Market cap
EV/EBITDA	Operative CAPEX/sales
Enterprise value Earnings before interest, tax, depreciation and amortization	Capital expenditure – divestments – acquisitions Sales
EV/EBIT	Net working capital
Enterprise value Operating profit	Current assets – current liabilities
Net debt	Capital employed/Share
Interest bearing debt – financial assets	Total assets – non-interest bearing debt Number of shares
Total assets	Gearing
Balance sheet total	<u>Net debt</u> Equity
Div yield, %	Debt/Equity, %
Dividend per share Price per share	Interest bearing debt Shareholders' equity + minority interest + taxed provisions
Payout ratio, %	Equity ratio, %
Total dividends Earnings before extraordinary items and taxes – income taxes + minority interest	Shareholders' equity + minority interest + taxed provisions Total assets – interest-free loans
ROCE, %	CAGR, %
Profit before extraordinary items + interest expenses+ other financial costs Balance sheet total – non-interest bearing debt (average)	Cumulative annual growth rate = Average growth per year
ROE, %	
Profit before extraordinary items and taxes – income taxes Shareholder's equity + minority interest + taxed provisions (average)	

Chemicals/Finland, May 3, 2023 Company update

Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 times per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 11th of May 2020. If recommendation is not given, it is not mentioned here.

Name(s) of the analyst(s): Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Plc. Production of the investment recommendation has been concluded on [3.5.2023, 9:00]. This report has been published on [3.5.2023, 15:15].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, May 3, 2023 Company update

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Plc is supervised by the Finnish Financial Supervision Authority.

Chemicals/Finland, May 3, 2023 Company update

Contact information SALES, TRADING AND RESEARCH

Equity, ETF and Derivatives Sales		Trading	
Joachim Dannberg Ari Laine Kimmo Lilja	+358 9 4766 9123 +358 9 4766 9115 +358 9 4766 9130	Lauri Vehkaluoto (Head) Pasi Väisänen Antti Kässi Miika Ronkanen	+358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120
Structured Investments		Equity Research	
Heikki Savijoki Aki Lakkisto	+358 9 4766 9726 +358 9 4766 9123	Jonas Forslund Joonas Ilvonen Jerker Salokivi Teemu Reiman	+358 9 4766 9314 +358 44 430 9071 +358 9 4766 9149 +358 40 352 6175
Evli Investment Solutions			
Johannes Asuja	+358 9 4766 9205		



EVLI BANK PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Fax +358 9 634 382
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI BANK PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000 Fax +46 (0)8 407 8001